~ $3.1 billion in Financial Assets ~ ~ Second Consecutive Quarter of Positive Operating Cash Flow ~ ~ Poised to Further Fulfill Mergers and Acquisitions Strategy ~ ~ Expanding into Rapidly Growing Predictions Market ~ SARASOTA, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) — Trump Media and Technology Group Corp. (Nasdaq, NYSE Texas: DJT) (“Trump Media” or the “Company”), operator of the social media platform Truth Social, the streaming platform Truth+, and the FinTech brand Truth.Fi, is announcing financial results for the fiscal quarter ending on September 30, 2025, and is filing its Form 10-Q with the Securities and Exchange Commission (the “SEC”) today. Trump Media ended the quarter with financial assets of $3.1 billion, comprising cash, restricted cash, short-term investments, trading securities,...

Substantial Quarterly Revenue Increase Year-Over-Year; Company Secures Historic Battery Recycling Contract with Potential $30 Million in Proceeds Reno, Nev., Nov. 07, 2025 (GLOBE NEWSWIRE) — American Battery Technology Company  (NASDAQ: ABAT), an integrated critical battery minerals company that is commercializing its internally-developed technologies for both primary battery critical minerals manufacturing and secondary critical minerals lithium-ion battery recycling, released its financial results for the first quarter of its fiscal year (FY) 2026, which ended on September 30, 2025. The quarter was marked by a substantial increase in cash balance, extinguishment of all outstanding debt and convertible notes, significant operational milestones, commercial facility enhancements, and major commercial wins that position American...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW CALGARY, Alberta, Nov. 07, 2025 (GLOBE NEWSWIRE) — High Arctic Energy Services Inc. (TSX: HWO) (the “Corporation” or “High Arctic”) released its third quarter 2025 financial and operating results. The unaudited condensed interim consolidated financial statements, and the management discussion & analysis (“MD&A”), for the three and nine months ended September 30, 2025 will be available on SEDAR+ at www.sedarplus.ca, and on High Arctic’s website at www.haes.ca. All amounts are denominated in thousands of Canadian dollars (“CAD”), unless otherwise indicated. Lonn Bate, Interim Chief Executive Officer commented: “High Arctic is pleased to have...

The net result as of September 30, 2025 improved by $1.1M compared to September 2024, following termination of a Convertible Bonds financing facility with Nice&GreenCNS (Vafidemstat)Received feedback from the FDA on Phase III PORTICO-2 trial in BPD; Company to revise protocol and resubmit Reinforcing company’s clinical, strategy and regulatory teams Expansion of ongoing Phase IIb in schizophrenia into other EU countries continues Preparations continue for new Phase II trial in aggression in Autism Spectrum DisorderOncology – Hematology (Iadademstat)Positive data in 1L AML to be presented at ASH with 100% ORR (88% CR) Positive data in R/R FLT3+ AML to be presented at ASH. RP2D selected Initiated enrollment in new Phase II trial in myeloproliferative neoplasms Enrollment in Phase I in MDS continues actively Initiated...

ASPEN-06 data to be presented at SITC demonstrates that evorpacept drove durable clinical benefit across all efficacy measures in HER2+ gastric cancer patients with high CD47 expressionPhase 2 ASPEN-09-Breast Cancer trial remains on track for FPI in Q4 2025 and will evaluate evorpacept efficacy by CD47 expression levelsPhase 1 trial for ALX2004, a novel EGFR-targeted ADC, is currently enrolling patients in the second dose cohort and on track to deliver initial safety data in 1H 2026Cash runway expected into Q1 2027 to support key milestones, including ALX2004 initial safety data in 1H 2026, interim data for ASPEN-09-Breast Cancer in Q3 2026Appointed Board Member Barbara Klencke, M.D., as Chief Medical OfficerCompany to host webcast including perspective from Breast Cancer Expert Dr. Peter Schmid on Friday, November 7, at...

Key Q3 2025 HighlightsDebt refinance completed Revenue and Adj. Revenue(1): $767M Pre-tax Income (Loss): $(38)M Adj. EBITDA Margin(1): 5.2% New Business Signings ACV(2): $111M Net ARR Activity Metric(2) (TTM): $25MFLORHAM PARK, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) — Conduent Incorporated (Nasdaq: CNDT), a global technology driven business process solutions and services company, today announced its third quarter 2025 financial results. Cliff Skelton, Conduent President and Chief Executive Officer, stated, “Q3 represents not only a quarter where we met guidance on Adjusted Revenue and Adjusted EBITDA Margin, but also the continuation of our drive toward year-over-year revenue growth. New business signings were consistent year over year and our Public Sector businesses had a particularly strong quarter, despite the cyclical nature...

Revenue of $38.2 Million, up 5% YoYAppointed new CRO as part of transition to an outcomes-based platform approach (All monetary figures are expressed in Canadian dollars unless otherwise stated) TORONTO, Nov. 07, 2025 (GLOBE NEWSWIRE) — illumin Holdings Inc. (TSX: ILLM and OTCQB: ILLMF) (“illumin” or the “Company”), a leader in digital advertising technology that empowers marketers to make smarter decisions about communicating with online consumers, today announced its financial results for the third quarter ended September 30, 2025. Third Quarter 2025 HighlightsThird quarter 2025 revenue rose 5% year-over-year to $38.2 million, driven by 103% year-over-year growth in Exchange service revenue, partially offset by a decrease in Managed service revenue. Exchange service revenue increased to $20.5 million. Self service revenue at...

— New preclinical data for PM577 in Wilson’s Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1’26, with initial clinical data expected in 2027 —  — Nominated PM647 as development candidate for Alpha-1 Antitrypsin Deficiency (AATD); on-track to file IND and/or CTA in mid-2026, with initial clinical data expected in 2027 — — Strengthened leadership team with the appointment of Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer — — Company to host virtual KOL event at 8:00am ET on Wednesday, November 12, 2025 to showcase Wilson’s Disease Strategy — CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today...

MONTREAL, Nov. 07, 2025 (GLOBE NEWSWIRE) — Boralex Inc. (“Boralex” or the “Corporation”) (TSX: BLX) is pleased to report its results for the third quarter of 2025. Highlights Financial resultsEBITDA(A)1, operating income and net earnings decline in Q3-2025:Production up 7% (9% on a Combined1 basis)2 from Q3-2024, owing mainly to the impact of newly commissioned sites in Europe, yet 13% (13%) below anticipated production1 because of unfavourable weather conditions in North America and to a lesser extent in Europe; Operating loss of $1 million (income of $13 million) in Q3-2025, down $8 million ($9 million) from Q3-2024; EBITDA(A) of $85 million ($108 million) in Q3-2025, down $2 million ($1 million) from Q3-2024 as a consequence of lower prices under short-term power purchase agreements in France, only partially offset by the...

NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) — AMC Networks Inc. (“AMC Networks” or the “Company”) (NASDAQ: AMCX) today reported financial results for the third quarter ended September 30, 2025. Chief Executive Officer Kristin Dolan said: “Our performance in the third quarter marks a key milestone in our transition from a cable networks business to a global streaming and technology focused content company. Streaming revenue growth accelerated and will represent our largest single source of domestic revenue this year. We again delivered healthy free cash flow and remain on track to achieve our increased outlook of $250 million in free cash for the full year. We have built the components of a modern media business that is nimble, independent and well suited to today’s environment and whatever comes next.” Operational...